Acute Phase Reaction, Infarct Size and In-Hospital Morbidity in Myocardial Infarction Patients Treated With Streptokinase or Recombinant Tissue Type Plasminogen Activator

References

• Kennedy J W, Ritchie J L, Davis K B, Fritz J K. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477–82
   PubMed Web of Science ®Google Scholar
• GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; I: 397–402
   Google Scholar
• GISSI. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987; II: 871–4
   Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; II: 349–60
   Google Scholar
• Wilcox R G, Von der Lippe G, Olsson C G, Jensen G, Hampton J R. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian study of early thrombolyis (ASSET). Lancet 1988; II: 525–30
   Google Scholar
• Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction and improved survival. Circulation 1989; 79: 441–5
   PubMed Web of Science ®Google Scholar
• Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet 1989; 1: 1367–9
   PubMedGoogle Scholar
• Smith S J, Bos G, Esseweld M R, Van Eijk H G, Gerbrandy J. Acute-phase proteins from the liver and enzymes from myocardial infarction; a guantitative relationship. Clin Chim Acta 1977; 81: 75–85
   PubMedGoogle Scholar
• Kushner I, Broder M L, Karp D. Control of acute phase response. The J Clin Invest 1978; 61: 235–42
   PubMed Web of Science ®Google Scholar
• de Beer F C, Hind C RK, Allan R M, Maserl A, Pepys M B. Measurement of serum C-reactive protein in myocardial ischemia and infarction. Br Heart J 1982; 47: 239–43
   PubMedGoogle Scholar
• Pietilä K, Harmoinen A, Pöyhönen L, Koskinen M, Heikkilä J, Ruosteenoja R. Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction. Br Heart J 1987; 58: 225–9
   PubMedGoogle Scholar
• Wurzburg U, Hennrich N, Lang H, et al. Bestimmung der Aktivität von Creatinkinase MB in Serum unter Verwendung inhibierender Antikröper. Klin Wochenschr 1976; 54: 357–60
   PubMedGoogle Scholar
• The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Recommended method forthe determination of creatine kinase in blood. Scand J Clin Lab Invest 1976; 36: 711–23
   PubMed Web of Science ®Google Scholar
• The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Experiences with the Scandinavian recommended methods for the determination of enzymes in blood. Scand J Clin Lab Invest 1981; 41: 107–16
   PubMedGoogle Scholar
• Harmoinen A. Immunoassay of C-reactive protein using the Hitachi 705E analyzer. J Clin Chem Biochem 1985; 23: 45–6
   PubMedGoogle Scholar
• Maury C PJ, Teppo A-M. Comparative study of serum amyloid-related protein, SAA, C-reactive protein and b2-microglobulin as markers of renal allograft rejection. Clin Nephrol 1984; 22: 284–92
   PubMedGoogle Scholar
• Rogers W J, McDaniel H G, Righetti A, et al. Correlation of angiographic estimates of myocardial infarct size and accumulated release of creatinine kinase isoenzyme in man. Circulation 1977; 56: 199–205
   PubMedGoogle Scholar
• Marhaug G, Harklau L, Olsen B, Husby G, Husebekk A, Wang H. Serum amyloid A protein in acute myocardial infarction. Acta Med Scand 1986; 220: 303–6
   PubMedGoogle Scholar
• Bausserman L L, Sadanlantz A, Saritelli A L, et al. Time course of serum amyloid A response in myocardial infarction. Clin Chim Acta 1989; 184: 297–306
   PubMedGoogle Scholar
• Shainkin-Kestenbaum R, Winikoff Y, Cristal N. Serum amyloid A concentrations during the course of acute ischaemic heart disease. J Clin Pathol 1886; 39: 235–7
   Google Scholar
• Mueller H S. Reperfusion therapy in acute myocardial infarction: Present status and controversy. Clin Cardiol 1990; 13: 239–46
   PubMedGoogle Scholar
• Perlmutter D H, Dinarello C A, Mizel S B, Colten H R. Cachectin/tumor necrosis factor regulates hepatic acute phase gene expression. J Clin Invest 1986; 79: 1349–54
   Google Scholar
• Ramadori G, Sipe J D, Dinarello C A, Mizel S B, Colten H R. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med 1985; 162: 930–6
   PubMed Web of Science ®Google Scholar
• Seliinger M J, McAdam K PWJ, Kaplan M M, Sipe J D, Vogel S N, Rosenstreich D L. Monokine-induced synthesis of serum amyloid A protein by hepatocytes. Nature 1980; 285: 498–500
   PubMedGoogle Scholar
• Selby P, Hobbs S, Viner C, et al. Tumour necrosis factor in man: Clinical and biological observations. Br J Cancer 1987; 56: 803–8
   PubMed Web of Science ®Google Scholar
• Cannon J G, Tompkins R G, Gelfand J A, et al. Circulating interleukin-1 and tumor necrosis factor inseptic shock and experimental endotoxin fewer. J Infect Dis 1990; 161: 79–84
   PubMed Web of Science ®Google Scholar
• Pye M, Rae A P, Cobbe S M. Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 1990; 63: 228–2230
   PubMedGoogle Scholar
• Barbash G I, Roth A, Hod H, et al. Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 261–6
   PubMedGoogle Scholar